Can we skip chemo-radiation for mid-rectal cancer
Part of Cancer, Digestive system clinical trials.
This study is for people with middle-stage rectal cancer (not too low, not too high) to see if they can safely avoid the usual chemotherapy and radiation before surgery. It's for those whose MRI shows the cancer is still confined to certain areas without dangerous spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your rectal cancer must be in the middle part of the rectum (6 to 12 cm from the anal opening).
- Your MRI scan must show one of these stages: cT2N+, cT3N0, or cT3N+.
- The cancer has not spread to the nearby outer layer (mesorectal fascia) on the MRI.
- No swollen lymph nodes in the side walls of the pelvis on the MRI.
- No signs of EMVI (cancer cells in tiny blood vessels) on the MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation therapy combined with chemotherapy and immunotherapy for people with mid-to-low rectal cancer that hasn't spread. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This trial tests how well a precise surgery removes the remaining rectal cancer after you have had radiation and chemotherapy. It is for people whose tumor has shrunk a lot but is still there, and the tumor is very low in the rectum.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Hear when a new Rectal Cancer Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.